GO:1904706 negative regulation of vascular associated smooth muscle cell proliferation: Signaling Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904706 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of vascular smooth muscle cell (VSMC) proliferation.
• Loss of negative regulation of VSMC proliferation drives neointima formation, pulmonary hypertension, and atherosclerosis-associated remodeling.
• Key molecular brakes include DUSP5, which dephosphorylates ERK1/2 to suppress VSMC proliferation and pulmonary hypertension, and BRD4770, which inhibits VSMC proliferation via SUV39H2-dependent histone methylation.
• Phenotypic switching of VSMCs from a contractile to a synthetic, proliferative state is a central event that negative regulators must counteract.
• Dysregulated non-coding RNAs, such as HIX003209, can override negative regulation by promoting VSMC migration and proliferation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to causally test whether a candidate gene negatively regulates VSMC proliferation.
Description
GO:1904706, negative regulation of vascular associated smooth muscle cell proliferation, is a biological process term that captures any mechanism which stops, prevents, or reduces the frequency, rate, or extent of vascular smooth muscle cell (VSMC) proliferation. VSMCs are the predominant cell type in the arterial media, and their ability to reversibly switch between a quiescent, contractile phenotype and a proliferative, synthetic phenotype is central to vascular homeostasis and disease. When negative regulatory pathways fail, excessive VSMC proliferation contributes to neointima formation after vascular injury, pulmonary hypertension, and atherosclerotic plaque progression. Understanding the molecular players that enforce this brake is therefore a major goal in cardiovascular research. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, genes, disease links, and experimental models relevant to GO:1904706.
negative regulation of vascular associated smooth muscle cell proliferation At A Glance
| GO ID | GO:1904706 |
|---|---|
| GO term | negative regulation of vascular associated smooth muscle cell proliferation |
| Ontology | biological_process |
| Synonym | down regulation of vascular smooth muscle cell proliferation; down-regulation of VSMC proliferation; inhibition of VSMC proliferation; negative regulation of VSMC proliferation |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of vascular smooth muscle cell proliferation |
| Related processes | VSMC phenotypic switching, apoptosis, migration, and extracellular matrix remodeling |
| Key negative regulators | DUSP5, BRD4770 (via SUV39H2), Cdon, KCNMB1, TWIST1 |
| Disease relevance | Pulmonary hypertension, neointima formation, vascular calcification, atherosclerosis |
What Is GO:1904706?
In our own words, GO:1904706 refers to any biological process that actively stops, prevents, or reduces the frequency, rate, or extent of vascular smooth muscle cell proliferation. It encompasses signaling cascades, transcriptional programs, epigenetic modifications, and non-coding RNA networks that keep VSMCs in a quiescent or contractile state and oppose their entry into the cell cycle.
Why Is negative regulation of vascular associated smooth muscle cell proliferation Important in Cell Biology?
GO:1904706 is critically important because uncontrolled VSMC proliferation is a hallmark of occlusive vascular diseases, including restenosis after angioplasty, pulmonary arterial hypertension, and atherosclerosis. Negative regulators of VSMC proliferation act as molecular brakes that preserve vessel patency and prevent pathological remodeling. Loss of these brakes, or gain of proliferative signals such as HIX003209, promotes neointima formation and right ventricular hypertrophy. Therefore, identifying and validating negative regulators of VSMC proliferation is essential for developing targeted therapies that selectively inhibit pathological VSMC growth without compromising normal vascular function.
• Prevents neointima formation after vascular injury by restraining VSMC proliferation.
• Suppresses pulmonary hypertension and right ventricular hypertrophy through DUSP5-mediated ERK1/2 inhibition.
• Counteracts VSMC phenotypic switching from contractile to synthetic states.
• Limits vascular calcification via Cdon repression of the Wnt/Runx2 axis.
• Provides therapeutic targets such as BRD4770 and SUV39H2 for anti-restenotic strategies.
• Is disrupted by non-coding RNAs like HIX003209 that promote VSMC migration and proliferation.
• Involves ion channel regulators such as KCNMB1 that maintain VSMC quiescence.
• Requires transcription factors like TWIST1 to sustain the contractile phenotype.
• Serves as a functional readout for CRISPR-based gene editing studies in vascular biology.
• Links basic VSMC biology to clinical outcomes in atherosclerosis and hypertension.
What Happens During negative regulation of vascular associated smooth muscle cell proliferation?
Initiation: Sensing Proliferative Cues and Phenotypic Switching
In simple terms: The process begins when VSMCs receive signals that would normally make them divide, and negative regulators step in to block that response.
VSMCs in healthy arteries are quiescent and contractile, but injury or growth factors can trigger phenotypic switching toward a synthetic, proliferative state. Negative regulation of VSMC proliferation is initiated when molecular sensors detect these pro-proliferative cues and activate counter-regulatory pathways. For example, reduced expression of KCNMB1 leads to VSMC phenotypic switch and apoptosis, indicating that ion channel subunits normally help maintain the quiescent state. Similarly, TWIST1 domains regulate smooth muscle cell phenotype, and loss of TWIST1 function promotes a proliferative phenotype. Thus, the first stage of GO:1904706 involves active maintenance of the contractile gene program and suppression of synthetic markers.
Signal Transduction: Phosphatases and Kinase Cascades
In simple terms: Specific enzymes act as brakes by turning off the growth signals inside the cell.
A central mechanism of negative regulation is the dephosphorylation of pro-proliferative kinases. DUSP5 is a dual-specificity phosphatase that inhibits smooth muscle cell proliferation by dephosphorylating ERK1/2, thereby suppressing pulmonary hypertension and right ventricular hypertrophy. This demonstrates that the MAPK/ERK pathway is a key target for negative regulation of VSMC proliferation. Other signaling brakes include Cdon, which suppresses vascular smooth muscle calcification via repression of the Wnt/Runx2 axis, indirectly limiting the osteogenic-like transition that accompanies proliferation. These examples show that GO:1904706 operates through dedicated phosphatase and receptor-mediated pathways that interrupt mitogenic signaling.
Epigenetic and Transcriptional Control
In simple terms: The cell can also lock the proliferative genes away by modifying how DNA is packaged.
Epigenetic modifiers are important effectors of negative regulation. BRD4770 inhibits vascular smooth muscle cell proliferation via SUV39H2, but not EHMT2, to protect against neointima formation. SUV39H2 is a histone methyltransferase that deposits repressive marks, leading to transcriptional silencing of pro-proliferative genes. This indicates that negative regulation of VSMC proliferation can be enforced at the chromatin level. Additionally, transcription factors such as TWIST1 regulate smooth muscle cell phenotype, and their functional domains are required to maintain the contractile state. Therefore, transcriptional and epigenetic reprogramming are core stages of GO:1904706.
Non-coding RNA Networks and Post-transcriptional Brakes
In simple terms: Small RNA molecules can fine-tune the levels of proteins that control cell division.
Non-coding RNAs participate in negative regulation by targeting mRNAs encoding proliferative factors. HIX003209 promotes vascular smooth muscle cell migration and proliferation through modulating miR-6089, indicating that this lncRNA overrides negative regulation. Conversely, miRNAs such as miR-6089 may act as negative regulators when not sponged by HIX003209. This stage highlights that the balance between pro-proliferative lncRNAs and anti-proliferative miRNAs determines the net output of GO:1904706. Dysregulation of this network can tip VSMCs toward excessive proliferation.
Integration with Apoptosis and Vascular Remodeling
In simple terms: The brakes on proliferation are often linked to signals that also control cell death and vessel repair.
Negative regulation of VSMC proliferation is closely integrated with apoptosis and extracellular matrix remodeling. Reduced KCNMB1 expression leads to VSMC phenotypic switch and apoptosis, suggesting that loss of this negative regulator promotes both proliferative and apoptotic responses depending on context. Sclerostin is involved in vascular pathophysiology, and its modulation affects VSMC behavior and calcification. These findings indicate that GO:1904706 does not operate in isolation but is part of a broader network that determines whether the vessel undergoes adaptive or maladaptive remodeling.
Key Genes Involved in GO:1904706 negative regulation of vascular associated smooth muscle cell proliferation
The following genes and proteins have been experimentally linked to negative regulation of vascular associated smooth muscle cell proliferation (GO:1904706) in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DUSP5 | Dephosphorylates ERK1/2 to inhibit VSMC proliferation | Suppresses pulmonary hypertension and right ventricular hypertrophy; key negative regulator |
| BRD4770 | Inhibits VSMC proliferation via SUV39H2-dependent histone methylation | Protects against neointima formation; epigenetic brake |
| SUV39H2 | Histone methyltransferase mediating BRD4770 effects | Epigenetic effector of negative regulation |
| KCNMB1 | Ion channel subunit maintaining VSMC quiescence | Reduced expression leads to phenotypic switch and apoptosis |
| TWIST1 | Transcription factor regulating smooth muscle cell phenotype | Domain-specific functions control contractile vs proliferative state |
| Cdon | Represses Wnt/Runx2 axis to suppress VSMC calcification | Links negative regulation to vascular calcification |
| HIX003209 | lncRNA that promotes VSMC migration and proliferation via miR-6089 | Overrides negative regulation; potential therapeutic target |
| miR-6089 | miRNA modulated by HIX003209 | Post-transcriptional regulator of VSMC proliferation |
| Sclerostin | Involved in vascular pathophysiology | Modulates VSMC behavior and calcification |
| EHMT2 | Histone methyltransferase not required for BRD4770 effects | Context-dependent role in VSMC proliferation |
| ERK1/2 | Pro-proliferative kinases inhibited by DUSP5 | Downstream targets of negative regulation |
| Runx2 | Transcription factor repressed by Cdon | Drives osteogenic transition in VSMCs |
| Wnt | Signaling pathway repressed by Cdon | Promotes VSMC calcification and proliferation |
| KCNMB1 channel | Regulates VSMC membrane potential and quiescence | Loss promotes synthetic phenotype |
| TWIST1 domain | Specific protein domains regulate SMC phenotype | Structure-function studies of negative regulation |
| miR-6089 sponge | HIX003209 acts as a sponge for miR-6089 | Non-coding RNA network controlling proliferation |
| DUSP5-ERK module | Signaling axis inhibiting VSMC proliferation | Therapeutic target for pulmonary hypertension |
| BRD4770-SUV39H2 axis | Epigenetic axis inhibiting VSMC proliferation | Target for anti-restenotic therapy |
How Is negative regulation of vascular associated smooth muscle cell proliferation Regulated?
GO:1904706 is regulated at multiple levels. DUSP5-mediated dephosphorylation of ERK1/2 provides a direct enzymatic brake on VSMC proliferation. Epigenetic regulation via BRD4770 and SUV39H2 silences pro-proliferative genes through histone methylation. Transcriptional control by TWIST1 maintains the contractile phenotype. Non-coding RNAs such as HIX003209 and miR-6089 modulate the stability of mRNAs encoding proliferative factors. Additionally, Cdon represses the Wnt/Runx2 axis to limit VSMC calcification and associated proliferation. These layers collectively determine the net activity of negative regulation in VSMCs.
negative regulation of vascular associated smooth muscle cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DUSP5 | Pulmonary hypertension and right ventricular hypertrophy | Knockout mouse or VSMC-specific overexpression |
| BRD4770/SUV39H2 | Neointima formation and restenosis | Pharmacological inhibition or CRISPR knockout in VSMCs |
| Cdon | Vascular calcification and atherosclerosis | Knockout mouse or VSMC-specific knockout |
| KCNMB1 | VSMC phenotypic switch and apoptosis | Knockdown or knockout in VSMC cultures |
| HIX003209/miR-6089 | VSMC migration and proliferation | lncRNA overexpression or miRNA mimic/inhibitor |
Pulmonary Hypertension and Right Ventricular Hypertrophy
Loss of DUSP5-mediated inhibition of smooth muscle cell proliferation leads to pulmonary hypertension and right ventricular hypertrophy. DUSP5 dephosphorylates ERK1/2, and its downregulation removes a critical brake on VSMC proliferation in pulmonary arteries. This demonstrates that GO:1904706 is directly relevant to the pathogenesis of pulmonary vascular disease.
Neointima Formation and Restenosis
BRD4770 inhibits vascular smooth muscle cell proliferation via SUV39H2 to protect against neointima formation. Neointima formation after vascular injury is driven by excessive VSMC proliferation, and epigenetic enforcement of negative regulation can limit this response. Therefore, GO:1904706 is a key protective process in restenosis.
Vascular Calcification and Atherosclerosis
Cdon suppresses vascular smooth muscle calcification via repression of the Wnt/Runx2 axis. Sclerostin is also involved in vascular pathophysiology, affecting VSMC behavior. These findings link negative regulation of VSMC proliferation to calcification and atherosclerotic remodeling.
VSMC Phenotypic Switch and Apoptosis
Reduced expression of KCNMB1 leads to VSMC phenotypic switch and apoptosis. TWIST1 domains regulate smooth muscle cell phenotype, and their dysfunction promotes proliferative states. Thus, disruption of GO:1904706 contributes to maladaptive VSMC plasticity in vascular disease.
From negative regulation of vascular associated smooth muscle cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DUSP5 increase VSMC proliferation? | DUSP5 knockout VSMC line or mouse model |
| Can BRD4770 inhibit VSMC proliferation via SUV39H2? | SUV39H2 knockout or point-mutation VSMCs treated with BRD4770 |
| Does Cdon repression of Wnt/Runx2 limit calcification? | Cdon knockout or overexpression in VSMCs |
| What is the role of KCNMB1 in VSMC phenotype? | KCNMB1 knockdown or knockout VSMCs |
| How does HIX003209 modulate miR-6089? | HIX003209 overexpression or knockout in VSMCs |
| Do TWIST1 domains regulate SMC phenotype? | TWIST1 domain-specific knock-in or deletion mutants |
How to Study the negative regulation of vascular associated smooth muscle cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on VSMC proliferation | Testing candidate negative regulators |
| CRISPR knock-in | Domain-specific or point-mutation effects | Dissecting TWIST1 domain functions |
| RNA-seq | Transcriptional changes during phenotypic switch | Identifying pro-proliferative gene signatures |
| ChIP-seq | Histone methylation and transcription factor binding | Mapping SUV39H2 and TWIST1 targets |
| EdU/MTT assay | DNA synthesis and cell viability | Quantifying VSMC proliferation |
| Scratch-wound assay | Cell migration | Assessing HIX003209 effects |
| Western blot | Protein phosphorylation and expression | Measuring ERK1/2 dephosphorylation by DUSP5 |
| Carotid injury model | Neointima formation in vivo | Validating anti-restenotic targets |
CRISPR Knockout and Knock-in Models
CRISPR-Cas9 knockout of candidate negative regulators such as DUSP5 or SUV39H2 allows direct testing of their role in VSMC proliferation. Knock-in of point mutations can dissect domain-specific functions, as shown for TWIST1. These models provide causal evidence for GO:1904706.
Transcriptomic and Epigenomic Profiling
RNA-seq and ChIP-seq can identify transcriptional and epigenetic changes underlying negative regulation. BRD4770 treatment alters histone methylation via SUV39H2, which can be mapped by ChIP-seq. TWIST1 binding sites can be identified by ChIP-seq to understand phenotype control.
Proliferation and Migration Assays
EdU incorporation, MTT, and scratch-wound assays quantify VSMC proliferation and migration. DUSP5 overexpression reduces proliferation, while HIX003209 increases migration and proliferation. These functional assays are standard readouts for GO:1904706.
In Vivo Vascular Injury Models
Carotid artery ligation or balloon injury models in mice assess neointima formation. BRD4770 protects against neointima formation in vivo. DUSP5-mediated inhibition suppresses pulmonary hypertension in animal models. These models validate in vitro findings.
How CRISPR Can Be Used to Study GO:1904706 negative regulation of vascular associated smooth muscle cell proliferation
Knockout
CRISPR knockout of DUSP5 or SUV39H2 in VSMCs can confirm their essential role in negative regulation of proliferation. Loss of DUSP5 is expected to increase ERK1/2 phosphorylation and proliferation. Knockout of SUV39H2 may abolish BRD4770-mediated inhibition.
Point Mutation
Point mutations in TWIST1 domains can reveal which residues are required for maintaining the contractile phenotype. Similarly, catalytically dead DUSP5 mutants can test whether phosphatase activity is required for inhibition of VSMC proliferation.
Knock-in
Knock-in of tagged DUSP5 or SUV39H2 allows endogenous localization and interaction studies. Tagged knock-in of TWIST1 can map domain-specific binding partners. These models preserve physiological expression levels.
Overexpression
Overexpression of DUSP5 or Cdon can suppress VSMC proliferation and calcification, respectively. Overexpression of HIX003209 promotes proliferation and migration, serving as a gain-of-function model. These studies establish sufficiency of negative regulators.
How EDITGENE Supports negative regulation of vascular associated smooth muscle cell proliferation Research
Researchers studying negative regulation of vascular associated smooth muscle cell proliferation-related genes often need to determine whether a candidate gene is causally involved in restraining VSMC growth or whether its modulation is merely correlative. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of vascular associated smooth muscle cell proliferation research.
Frequently Asked Questions About negative regulation of vascular associated smooth muscle cell proliferation
What is GO:1904706?
GO:1904706 is the Gene Ontology term for negative regulation of vascular associated smooth muscle cell proliferation, describing any process that stops, prevents, or reduces VSMC proliferation.
What genes are involved in negative regulation of vascular smooth muscle cell proliferation?
Key genes include DUSP5, BRD4770, SUV39H2, KCNMB1, TWIST1, Cdon, and the lncRNA HIX003209.
How does DUSP5 inhibit VSMC proliferation?
DUSP5 dephosphorylates ERK1/2, thereby suppressing smooth muscle cell proliferation and pulmonary hypertension.
What is the role of BRD4770 in VSMC proliferation?
BRD4770 inhibits VSMC proliferation via SUV39H2-dependent histone methylation and protects against neointima formation.
How is VSMC phenotypic switching related to GO:1904706?
Phenotypic switching from contractile to synthetic states promotes proliferation, and negative regulators like KCNMB1 and TWIST1 counteract this switch.
What diseases are linked to loss of negative regulation of VSMC proliferation?
Pulmonary hypertension, neointima formation, restenosis, vascular calcification, and atherosclerosis.
What experimental models study negative regulation of VSMC proliferation?
CRISPR knockout, knock-in, overexpression VSMC lines, and in vivo carotid injury or pulmonary hypertension models.
How does HIX003209 affect VSMC proliferation?
HIX003209 promotes VSMC migration and proliferation by modulating miR-6089, overriding negative regulation.
What is the role of Cdon in vascular smooth muscle cells?
Cdon suppresses vascular smooth muscle calcification via repression of the Wnt/Runx2 axis.
Why is GO:1904706 important for drug discovery?
It identifies molecular brakes that can be targeted to prevent pathological VSMC proliferation in cardiovascular disease.
Conclusion
GO:1904706, negative regulation of vascular associated smooth muscle cell proliferation, is a fundamental biological process that protects against occlusive vascular diseases. Key effectors such as DUSP5, BRD4770/SUV39H2, Cdon, KCNMB1, and TWIST1 enforce this brake through phosphatase, epigenetic, and transcriptional mechanisms. Dysregulation by non-coding RNAs like HIX003209 contributes to disease. CRISPR-based models are indispensable for causally testing these regulators and for developing targeted therapies.
References
- 1. Liu H et al.. 2025. Reduced expression of KCNMB1 leads to vascular smooth muscle cell phenotypic switch and apoptosis.. Biochem Pharmacol 241:117151 PMID: 40653026
- 2. Catalano A et al.. 2020. Sclerostin and Vascular Pathophysiology.. Int J Mol Sci 21(13) PMID: 32640551
- 3. Dy DCM et al.. 2025. Functional analysis of TWIST1 domains regulating smooth muscle cell phenotype.. Front Cardiovasc Med 12:1659847 PMID: 41246007
- 5. Ahn BY et al.. 2023. Cdon suppresses vascular smooth muscle calcification via repression of the Wnt/Runx2 Axis.. Exp Mol Med 55(1):120-131 PMID: 36609601
- 6. Chen TQ et al.. 2023. BRD4770 inhibits vascular smooth muscle cell proliferation via SUV39H2, but not EHMT2 to protect against neointima formation.. Hum Cell 36(5):1672-1688 PMID: 37306883
- 7. Shi X et al.. 2020. HIX003209 promotes vascular smooth muscle cell migration and proliferation through modulating miR-6089.. Aging (Albany NY) 12(10):8913-8922 PMID: 32463793
- 8. Ferguson BS et al.. 2021. DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy.. Am J Physiol Heart Circ Physiol 321(2):H382-H389 PMID: 34142888
